Imfinzi squares up to Keytruda with a Padcev combo
The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
MacroGenics changes its tune on Linnet
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Ideaya exits Werner and Pol theta
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
Cytospire’s backers buy in as Pfizer exits
No sooner does one gammadelta-focused biotech die than another takes its place.
BeOne chooses degradation over inhibition
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
ASCO 2026 preview – Celcuity gets a mutant coup
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
